Subhangi Das, Bankura Sammilani College
With the phototherapic development which is also a type of light-induced treatment of cancer, several biomaterials are newly designed as photo-absorbing /sensitizing agents or effecting carriers to enhance the therapeutic efficacy and effective nature of phototherapy.
Recently, the immune system responses produced by phototherapy. Which have been explored widely and triggered by tumour-associated antigens (TAAs) releasing from the dead cancer cells after phototherapy. With both secretion of damage-associated molecular patterns (DAMPs) and various pro-inflammatory cytokines/factors.
To put together the immunological responses produced by phototherapy, various immunological agents such as nano / macro materials are introduced to boost the immune system to recognise and kill cancer cells. These responses are further put to work in synergy with other immunotherapies like Immune Checkpoint Blockage (ICB) Chimeric Antigen Receptor (CAR) T-cell and cytokine therapy which has given increased rates in immune response rates and successful therapeutic outcomes. This article focuses on the recent progress in engineering biomaterials for enhanced photoimmunotherapy and it also discusses the challenges, opportunities and prospects in this field.
This article focuses on the recent progress in engineering biomaterials for enhanced photoimmunotherapy and it also discusses the challenges, opportunities and prospects in this field. Researchers are trying to conjugate various other monoclonal antibodies to phthalocyanine, leading to a huge flexible therapeutic platform.
Also read: Gene-editing: The Revolution has begun.
Citation: Biomaterials Science Emerging Investigators 2021 https://doi.org/10.1039/D0BM01154A
Assessing the Changing Treatment Landscape in Triple-Negative Breast Cancer !
Sagnik Nag, Amity University Kolkata Breast cancer is among the second largest cause of deaths among women related to cancer. The development of breast cancer is a multi-step process that involves numerous cell types and its treatment remains shrouded with many challenges. Triple-negative breast cancers (TNBC) is accounted for 10-15% of all breast cancers. Triple-negative breast […]